Amneal Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Amneal Pharmaceuticals Inc 公司

Amneal Pharmaceuticals, Inc. 是一家全球性製藥公司，開發、生產、營銷和分銷一系列基本藥物。其仿製藥部門包括超過 270 個產品系列的零售和機構產品組合，涵蓋一系列劑型和給藥系統，包括速釋和緩釋口服固體、粉末、液體、無菌注射劑、鼻噴霧劑、吸入和呼吸產品、生物仿製藥、眼科、薄膜、透皮貼劑和外用藥。其專科部門從事品牌藥品的開發、推廣、銷售和分銷，重點是治療中樞神經系統疾病（包括帕金森病和內分泌疾病）的產品。其 AvKARE 部門主要向政府機構提供藥品、醫療和外科產品和服務，主要針對美國國防部和美國退伍軍人事務部。

公司簡介

公司代碼AMRX

公司名稱Amneal Pharmaceuticals Inc

上市日期Nov 18, 2009

CEOMr. Chintu Patel

員工數量8100

證券類型Ordinary Share

年結日Nov 18

公司地址400 Crossing Boulevard, 3rd Floor

城市BRIDGEWATER

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編08807

電話19089473120

網址https://amneal.com/

公司代碼AMRX

上市日期Nov 18, 2009

CEOMr. Chintu Patel

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Chintu Patel

Co-Chief Executive Officer, Co-Founder, Director

25.62M

+1.39%

Mr. Gautam Patel

Director

1.61M

-8.60%

Mr. Anastasios G. (Tasos) Konidaris

Chief Financial Officer, Executive Vice President

621.88K

+32.21%

Mr. Shlomo Yanai

Independent Director

285.99K

+16.38%

Ms. Nikita Shah

Chief Human Resources Officer, Executive Vice President

191.40K

-55.89%

Ms. Deborah M. (Deb) Autor

Independent Director

93.66K

+75.39%

Mr. Chirag Patel

President, Co-Chief Executive Officer, Co-Founder, Director

--

Mr. Ted Nark

Independent Director

--

Mr. Paul M. Meister

Independent Chairman of the Board

--

Mr. John J. Kiely

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Chintu Patel

Co-Chief Executive Officer, Co-Founder, Director

25.62M

+1.39%

Mr. Gautam Patel

Director

1.61M

-8.60%

Mr. Anastasios G. (Tasos) Konidaris

Chief Financial Officer, Executive Vice President

621.88K

+32.21%

Mr. Shlomo Yanai

Independent Director

285.99K

+16.38%

Ms. Nikita Shah

Chief Human Resources Officer, Executive Vice President

191.40K

-55.89%

Ms. Deborah M. (Deb) Autor

Independent Director

93.66K

+75.39%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Oral solid

178.95M

25.73%

Distribution

104.89M

15.08%

Central Nervous System

67.61M

9.72%

Other dosage forms

56.42M

8.11%

Government label

50.14M

7.21%

其他

237.40M

34.14%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Oral solid

178.95M

25.73%

Distribution

104.89M

15.08%

Central Nervous System

67.61M

9.72%

Other dosage forms

56.42M

8.11%

Government label

50.14M

7.21%

其他

237.40M

34.14%

股東統計

更新時間: 8月15日週五

持股股東

股東類型

持股股東

佔比

Patel (Tushar Bhikhubhai)

15.47%

Patel (Chintu)

8.16%

Patel (Dipan)

7.59%

Patel (Chirag K)

7.05%

Akram (Mahesh)

6.55%

其他

55.20%

持股股東

佔比

Patel (Tushar Bhikhubhai)

15.47%

Patel (Chintu)

8.16%

Patel (Dipan)

7.59%

Patel (Chirag K)

7.05%

Akram (Mahesh)

6.55%

其他

55.20%

股東類型

持股股東

佔比

Individual Investor

46.44%

Investment Advisor

17.42%

Hedge Fund

12.07%

Investment Advisor/Hedge Fund

10.83%

Private Equity

3.93%

Research Firm

1.21%

Pension Fund

0.24%

Bank and Trust

0.20%

Family Office

0.02%

其他

7.65%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

430

283.67M

90.50%

-32.81M

2025Q1

437

285.44M

91.08%

-30.39M

2024Q4

413

285.94M

92.29%

-32.70M

2024Q3

398

304.85M

98.50%

-8.45M

2024Q2

391

304.30M

98.56%

+52.65M

2024Q1

375

272.60M

88.40%

+17.73M

2023Q4

366

275.21M

90.82%

+129.07M

2023Q3

354

120.75M

78.38%

-3.68M

2023Q2

353

115.91M

75.59%

-7.89M

2023Q1

359

114.33M

74.58%

-11.39M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Patel (Tushar Bhikhubhai)

48.58M

15.5%

-5.00M

-9.33%

Mar 14, 2025

Patel (Chintu)

25.62M

8.17%

+351.47K

+1.39%

Mar 14, 2025

Patel (Dipan)

23.83M

7.6%

--

Mar 14, 2025

Patel (Chirag K)

22.13M

7.06%

+345.41K

+1.59%

Mar 14, 2025

Akram (Mahesh)

20.56M

6.56%

-6.30M

-23.45%

Mar 31, 2025

The Vanguard Group, Inc.

15.71M

5.01%

+920.76K

+6.23%

Mar 31, 2025

TPG Capital, L.P.

12.33M

3.93%

--

Mar 31, 2025

Rubric Capital Management LP

10.74M

3.43%

+14.20K

+0.13%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.14M

3.55%

-80.92K

-0.72%

Mar 31, 2025

Citadel Advisors LLC

7.49M

2.39%

-1.49M

-16.58%

Mar 31, 2025

持股ETF

更新時間: 9月6日週六

機構名稱

佔比

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.3%

Vanguard US Multifactor ETF

0.22%

First Trust Multicap Growth Alphadex Fund

0.12%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.06%

Global X Russell 2000 ETF

0.05%

iShares Morningstar Small-Cap Value ETF

0.04%

Fidelity MSCI Health Care Index ETF

0.03%

Dimensional US Core Equity 1 ETF

0.01%

DFA Dimensional US Core Equity Market ETF

0%

iShares Russell 3000 ETF

0%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比2.3%

Vanguard US Multifactor ETF

佔比0.22%

First Trust Multicap Growth Alphadex Fund

佔比0.12%

JPMorgan BetaBuilders US Small Cap Equity ETF

佔比0.06%

Global X Russell 2000 ETF

佔比0.05%

iShares Morningstar Small-Cap Value ETF

佔比0.04%

Fidelity MSCI Health Care Index ETF

佔比0.03%

Dimensional US Core Equity 1 ETF

佔比0.01%

DFA Dimensional US Core Equity Market ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Amneal Pharmaceuticals Inc

9.810USD

Amneal Pharmaceuticals Inc

9.810

概覽

公司

財務

分析